{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:39:50Z","timestamp":1790278790123,"version":"4.1.0"},"reference-count":15,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Child and Adolescent Psychopharmacology"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                    <jats:title>Importance:<\/jats:title>\n                    <jats:p>Selective serotonin reuptake inhibitors (SSRIs) and cognitive behavioral therapy are the first-line treatments for pediatric obsessive-compulsive disorder (OCD) populations. Due to their limited effectiveness, additional treatment options are needed. A new potential pharmacological medication treatment avenue for OCD is intravenous (IV) ketamine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This study aimed to establish the feasibility, acceptability, and preliminary efficacy of an IV ketamine infusion for the treatment of refractory OCD in adolescents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>In this clinical pilot trial, every participant received IV ketamine infusion. Symptom severity and side effects were assessed daily for 2 weeks following the infusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting:<\/jats:title>\n                    <jats:p>Study procedures were conducted at the New York State Psychiatric Institute, including a combination of in-person visits and phone calls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants:<\/jats:title>\n                    <jats:p>Five adolescents with OCD (age M, SD: 16.6 \u00b1 1.5), who had previously failed trials of first-line treatments were enrolled.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Intervention:<\/jats:title>\n                    <jats:p>All participants received an IV infusion of 0.5 mg\/kg ketamine hydrochloride.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures:<\/jats:title>\n                    <jats:p>A multimethod approach was applied, including physiological, self-report, and clinician-rated measures. To assess feasibility and acceptability, vital signs, electrocardiogram suicidality, self-reported adverse events, and dissociative symptoms were obtained. Obsessive-compulsive (OC) (Yale-Brown Obsessive Compulsive Challenge Scale, CY-BOCS) and depressive symptom severity, as well as global clinical impression, were assessed to investigate preliminary efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The mean (SD) pre- and 14-day posttreatment CY-BOCS were 29 (5.5) and 26.2 (5.6). There were no incidents of abnormal vital signs, mortality, or suicidal ideation in the 2 weeks following the infusion. All participants experienced mild dissociative symptoms in the 40 minutes after the IV ketamine infusion. Descriptively, OC symptom severity decreased immediately after the infusion but was not maintained over the course of the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Clinical Significance:<\/jats:title>\n                    <jats:p>Ketamine is well-tolerated in adolescents with OCD and therefore appropriate for further efficacy testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration:<\/jats:title>\n                    <jats:p>ClinicalTrials.gov Identifier: NCT02422290.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/cap.2024.0127","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T11:46:41Z","timestamp":1738583201000},"page":"167-170","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Ketamine Treatment for Pediatric Refractory Obsessive: Five Open Label Cases"],"prefix":"10.1177","volume":"35","author":[{"given":"Hannah S.","family":"Ishimuro","sequence":"first","affiliation":[{"name":"Department of Psychology, University of Denver, Denver, CO, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula K.","family":"Yanes-Lukin","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA."},{"name":"New York State Psychiatric Institute, New York, NY, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo H.","family":"Goldberg","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA."},{"name":"New York State Psychiatric Institute, New York, NY, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Blair","family":"Simpson","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA."},{"name":"New York State Psychiatric Institute, New York, NY, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7194-5090","authenticated-orcid":false,"given":"Moira A.","family":"Rynn","sequence":"additional","affiliation":[{"name":"Duke University School of Medicine, Durham, NC, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2012.05.028"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1024465317902"},{"issue":"2","key":"e_1_3_3_4_1","first-page":"214","article-title":"Efficacy of intravenous ketamine in adolescent treatment-resistant depression: A randomized midazolam-controlled trial","volume":"20","author":"Dwyer JB","year":"2022","unstructured":"Dwyer JB, , Landeros-Weisenberger A, , Johnson JA, et al. Efficacy of intravenous ketamine in adolescent treatment-resistant depression: A randomized midazolam-controlled trial. Focus, 2022; 20(2):214\u2013251.","journal-title":"Focus"},{"key":"e_1_3_3_5_1","first-page":"183","volume-title":"Psychobiology of OCD","author":"Goodman WK","year":"1989","unstructured":"Goodman WK, , Price LH, , Woods SW, et al. Pharmacologic challenges in obsessive-compulsive disorder. In: Psychobiology of OCD. Springer; 1989. 183."},{"key":"e_1_3_3_6_1","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy W","year":"1976","unstructured":"Guy W. ed. ECDEU Assessment Manual for Psychopharmacology. US Department of Heath, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration; 1976."},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9592.2004.01224.x"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S211703"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2019.00523"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/0149-7189(79)90094-6"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.2103\/7\/tp.2019.10.02"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.16.1969"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10111704"},{"key":"e_1_3_3_14_1","first-page":"979","article-title":"Children\u2019s depression rating scale revised","volume":"21","author":"Poznanski EO","year":"1985","unstructured":"Poznanski EO, , Freeman LN, , Mokros HB. Children\u2019s depression rating scale revised. Psychopharmacol Bull, 1985; 21:979\u2013989.","journal-title":"Psychopharmacol Bull"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2013.150"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199706000-00023"}],"container-title":["Journal of Child and Adolescent Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cap.2024.0127","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2024.0127","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2024.0127","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:57:10Z","timestamp":1777388230000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cap.2024.0127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1089\/cap.2024.0127"],"URL":"https:\/\/doi.org\/10.1089\/cap.2024.0127","relation":{},"ISSN":["1044-5463","1557-8992"],"issn-type":[{"value":"1044-5463","type":"print"},{"value":"1557-8992","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]}}}